High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
299.17M
+3.09%
0.242
+15.4%
269.74M
+5.98%
0.175
+24.74%
307.58M
+4.5%
0.231
+15.7%
Estimates Revision
The market is revising No Change the revenue expectations for Sotera Health Company (SHC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.02%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+6.02%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast SHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHC is 18.60 USD with a low forecast of 16.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 16.560
Low
16.00
Averages
18.60
High
21.00
Current: 16.560
Low
16.00
Averages
18.60
High
21.00
BMO Capital
Sean Dodge
Outperform
initiated
$19
2025-11-12
Reason
BMO Capital
Sean Dodge
Price Target
$19
2025-11-12
initiated
Outperform
Reason
BMO Capital analyst Sean Dodge initiated coverage of Sotera Health with an Outperform rating and $19 price target. The macro and industry headwinds that have dragged on Solera's growth over the last 2-3 years have finally begun to dissipate, which paves the way for a re-acceleration in both revenue and EBITDA growth back toward management's longer-range 5%-7% and 5%-8% targets, the analyst tells investors in a research note. Ongoing litigation remains a risk, but is already discounted into the current valuation.
JPMorgan
Neutral
maintain
$14 -> $16
2025-11-05
Reason
JPMorgan
Price Target
$14 -> $16
2025-11-05
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Sotera Health to $16 from $14 and keeps a Neutral rating on the shares. The company reported a Q3 beat but the litigation overhang remains, the analyst tells investors in a research note.
Piper Sandler
Neutral
maintain
$15 -> $17
2025-11-05
Reason
Piper Sandler
Price Target
$15 -> $17
2025-11-05
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Sotera Health to $17 from $15 and keeps a Neutral rating on the shares. The firm notes the company announced Q3 results that included revenue that came in above Street's on upside from Nordion, and as EBITDA% progress continues to be evident in Sterigenics. Guidance is also moving slightly higher to account mainly for the Q3 beat, a wise expectation management move that should make for a favorable setup through year-end and into Q4 reporting, especially knowing that the outsourced sterilization market is back to growing at attractive normalized rates, Piper adds.
Barclays
Overweight
maintain
$19 -> $20
2025-11-05
Reason
Barclays
Price Target
$19 -> $20
2025-11-05
maintain
Overweight
Reason
Barclays raised the firm's price target on Sotera Health to $20 from $19 and keeps an Overweight rating on the shares. The company reported a "solid" quarter as the business is operating at a normal level following the last year of supply chain issues, the analyst tells investors in a research note.
Barclays
Luke Sergott
Overweight
maintain
$13 -> $17
2025-08-08
Reason
Barclays
Luke Sergott
Price Target
$13 -> $17
2025-08-08
maintain
Overweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Sotera Health to $17 from $13 and keeps an Overweight rating on the shares following the Q2 report. The firm believes the shares are undervalued on the core business but that Sotera's litigation overhang limits what investors are willing to pay.
Barclays
Overweight
maintain
$15 -> $13
2025-06-24
Reason
Barclays
Price Target
$15 -> $13
2025-06-24
maintain
Overweight
Reason
Barclays lowered the firm's price target on Sotera Health to $13 from $15 and keeps an Overweight rating on the shares as part of a Q2 preview for the life science and diagnostic tools sector. Sentiment on the group is shifting more positive on the notion that many of the unknown headwinds around policy changes, namely National Institutes of Health budgetary cuts and pharma tariffs, are likely to prove less severe than feared, the analyst tells investors in a research note. Barclays still favors businesses exposed to commercial and clinical volumes, mainly bioprocessing and diagnostics.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Sotera Health Co (SHC.O) is 17.96, compared to its 5-year average forward P/E of 19.96. For a more detailed relative valuation and DCF analysis to assess Sotera Health Co 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
19.96
Current PE
17.96
Overvalued PE
25.74
Undervalued PE
14.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
12.65
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.41
Undervalued EV/EBITDA
8.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.64
Current PS
0.00
Overvalued PS
6.43
Undervalued PS
2.86
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 140.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SHC News & Events
Events Timeline
(ET)
2025-12-04
07:50:00
Goldman Sachs Sets Offering Price Range at $19.70-$20.00
2025-11-06 (ET)
2025-11-06
16:39:28
Sotera Health to Offer 30 Million Shares of Common Stock to Investors
2025-11-04 (ET)
2025-11-04
07:12:41
Sotera Health increases FY25 adjusted EPS forecast to 81c-86c, up from 75c-82c
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-13BenzingaBMO Capital Begins Coverage of Sotera Health with Outperform Rating and Sets Price Target at $19
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
8.5
11-07NewsfilterSotera Health Unveils Secondary Common Stock Offering
Preview
4.0
11-06BenzingaJP Morgan Keeps Neutral Rating on Sotera Health, Increases Price Target to $16
Sign Up For More News
People Also Watch
FAQ
What is Sotera Health Co (SHC) stock price today?
What is Sotera Health Co (SHC)'s business?
What is the price predicton of SHC Stock?
What is Sotera Health Co (SHC)'s revenue for the last quarter?
What is Sotera Health Co (SHC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sotera Health Co (SHC)'s fundamentals?
How many employees does Sotera Health Co (SHC). have?